A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs SLV 341 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Abbott Healthcare Products
  • Most Recent Events

    • 22 Jul 2009 Planned number of patients changed from 110 to 87 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top